Uveitogenicity is associated with a Th1-like lymphokine profile: Cytokine-dependent modulation of early and committed effector T cells in experimental autoimmune uveitis

被引:85
作者
Xu, H
Rizzo, LV
Silver, PB
Caspi, RR
机构
[1] Laboratory of Immunology, NEI, National Institutes of Health, Bethesda
关键词
D O I
10.1006/cimm.1997.1121
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
This study addresses the nature of the pathogenic effector T cell in experimental autoimmune uveoretinitis and the effect of different cytokines on these cells in vitro. Lymph node cells of B10.RIII mice immunized with the uveitogenic peptide 161-180 of interphotoreceptor retinoid binding protein were cultured with the peptide with or without IL-12, IL-4, or anti-IL-4. An antigen-specific T cell line was subsequently derived from these cells. Primary cultures of immune lymph node cells stimulated with the peptide proliferated and produced IL-2 and some IL-4, but no IFN-gamma. The addition of recombinant IL-12 resulted in abundant production of IFN-gamma, which was blocked by the addition of IL-4 and was enhanced by anti-IL-4. Only those cultures that produced IFN-gamma in vitro were uveitogenic in vivo. A long-term uveitogenic T cell line, initially derived in the presence of IL-12, produced IFN-gamma and IL-2, but not IL-4, and was CD4(+) (Th1-like). Antigen-specific proliferation and IFN-gamma production of the line were enhanced by exogenous IL-4, TGF-beta, IL-2, IL-6, IL-7, and IL-9 and were inhibited by IL-10 and TNF-alpha. Our results provide support for the hypothesis that the uveitogenic effector T cell has a Th1-like phenotype. Furthermore, the data suggest that the effects of the cytokine milieu on fully differentiated Th1 effecters may differ considerably from their effects on less mature stages of antigen-specific T cells.
引用
收藏
页码:69 / 78
页数:10
相关论文
共 42 条
[1]   DISTRIBUTION OF TRANSFORMING GROWTH-FACTOR-BETA ISOFORMS IN THE MAMMALIAN RETINA [J].
ANDERSON, DH ;
GUERIN, CJ ;
HAGEMAN, GS ;
PFEFFER, BA ;
FLANDERS, KC .
JOURNAL OF NEUROSCIENCE RESEARCH, 1995, 42 (01) :63-79
[2]  
[Anonymous], AUTOIMMUNE DIS MODEL
[3]  
CASPI RR, 1988, J IMMUNOL, V140, P1490
[4]  
CASPI RR, 1994, J IMMUNOL, V152, P890
[5]  
Caspi RR, 1996, J IMMUNOL, V157, P2668
[6]  
CASPI RR, 1986, J IMMUNOL, V136, P928
[7]  
CASPI RR, 1994, INT CONGR SER, V1068, P55
[8]  
CERWENKA A, 1994, J IMMUNOL, V153, P4367
[9]  
CHRIST M, 1994, J IMMUNOL, V153, P1936
[10]  
COUSINS SW, 1991, INVEST OPHTH VIS SCI, V32, P2201